191 |
Pathogenesis and Pathologic Features of Vulnerable Plaque |
Erling Falk |
Jun. 16. 06 |
190 |
Conor Erodable Polymer Paclitaxel Eluting Stent- Indian & European Experience |
Upendra Kaul |
Jun. 09. 06 |
189 |
Multivessel and Multilesion Stenting in Drug Eluting Era: Results from ERACI III Trial |
Alfredo Rodriguez |
Jun. 09. 06 |
188 |
BEACON Registry: An All-Comers Trial of Biolimus A9 Eluting Stent |
Tian-Hai Koh |
Jun. 09. 06 |
187 |
MEDISTRA "Excel" Drug Eluting Stent Trial (MEDISTRA): Medium-To-Long Term Outcome |
Teguh Santoso |
Jun. 09. 06 |
186 |
Jupiter I Beta and Jupiter II Meta-Analysis |
Thierry Lefevre |
Jun. 09. 06 |
185 |
The Xtent™ DES System: The Single Solution for Multilesion, Multivessel, and Long Lesion Treatment |
Eberhard Grube |
Jun. 09. 06 |
184 |
Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US NOBORI Clinical Trial Program |
Eberhard Grube |
Jun. 02. 06 |
183 |
Radiocontrast Nephropathy: Still the Achilles' Heel of Interventional Cardiology |
Roxana Mehran |
Jun. 02. 06 |
182 |
DES Thrombosis: Is It Real and Is It Worse? New Approaches to Solving It ? |
David R. Holmes |
Jun. 02. 06 |